Azenosertib's Cyclin E1 OS Split: Compelling Biomarker Signal, Insufficient Evidence for Approval

Zentalis' Azenosertib Shows Promising Survival in Ovarian Cancer

Zentalis Pharmaceuticals announced interim overall survival results from the DENALI Part 1b study (GOG-3066) evaluating azenosertib in 102 patients with platinum-resistant ovarian cancer who had received one to five previous lines of treatment, including bevacizumab. Patients in the Cyclin E1-positive cohort achieved a median overall survival of 15.8 months, significantly higher than the 7.5 months recorded in the Cyclin E1-negative group. This data suggests Cyclin E1 as a predictive biomarker for azenosertib response, with no new safety signals identified.

• The DENALI Part 1b study demonstrated a significant difference in median overall survival based on Cyclin E1 status. Cyclin E1-positive patients treated with azenosertib achieved 15.8 months, which compares favorably with historical single-agent chemotherapy benchmarks, identifying Cyclin E1 as a crucial predictive biomarker for drug response in platinum-resistant ovarian cancer.
• The study enrolled 102 participants with platinum-resistant ovarian cancer, all of whom had undergone between one and five prior lines of treatment, including mandatory bevacizumab exposure. Each participant received 400mg of azenosertib once daily. Retrospective immunohistochemistry testing confirmed 48 Cyclin E1-positive cases and 46 Cyclin E1-negative cases, providing a clear basis for the biomarker analysis.
• Zentalis is advancing azenosertib through its ongoing registration-intended DENALI program, which includes Parts 2a, 2b, and 2c, with Part 2a having selected the 400mg regimen and Part 2b having completed enrolment. Additionally, the company is progressing Aspenova, a randomized Phase III confirmatory study designed to compare 400mg azenosertib against investigator-selected chemotherapy in approximately 420 patients.

Addressing Unmet Needs in Platinum-Resistant Ovarian Cancer with Azenosertib

Platinum-resistant ovarian cancer (PROC) remains a disease of significant unmet need, defined by progression within 6 months of platinum-based chemotherapy and historically limited to non-platinum single-agent therapy plus bevacizumab as the standard of care. Recent clinical and translational research has increasingly focused on biomarker-selected populations and novel therapeutic mechanisms to improve outcomes in this challenging setting.

• Biomarker-unselected populations with poor prognosis: Conventional chemotherapy provides only modest benefit in PROC, and immune checkpoint inhibitors have shown limited efficacy in unselected populations, underscoring the need for strategies that deliver survival improvements regardless of biomarker status. Approaches such as the addition of the glucocorticoid receptor antagonist relacorilant to nab-paclitaxel and immune-chemotherapy combinations such as pembrolizumab plus paclitaxel with or without bevacizumab have demonstrated survival improvements even in biomarker-unselected populations.

• FRα-high expressing tumors: Patients with high folate receptor alpha (FRα) expression represent a clinically actionable population. Mirvetuximab soravtansine (MIRV), the first FDA-approved FRα-targeting antibody-drug conjugate, demonstrated superiority over chemotherapy in FRα-positive PROC in the MIRASOL trial, improving median progression-free survival (5.6 vs. 3.9 months) and overall survival (16.5 vs. 12.8 months; HR 0.67). Real-world data confirm clinical benefit even in heavily pretreated patients, with 44% of one cohort having more than 3 prior lines of treatment.

• Patients with low or variable FRα expression: Current FRα-directed therapy with MIRV (Elahere) requires high expression levels for eligibility, leaving patients with low or heterogeneous FRα expression without a targeted option. Next-generation ADCs such as AZD5335, a topoisomerase-1 inhibitor ADC, achieved an overall response rate of 82% across ovarian cancer patient-derived xenografts (n=17), with anti-tumor responses observed in models expressing both high and low levels of FRα, and demonstrated efficacy in models of acquired Elahere-resistance.

• Patients with BRCA mutations in the recurrent setting: BRCAmut patients with platinum-resistant recurrent ovarian cancer represent a population with distinct and less favorable outcomes on standard salvage chemotherapy. Paclitaxel monotherapy was associated with a median overall survival of 11 months (95% CI 8.28 to 13.72) in BRCAmut patients compared with 18 months (95% CI 16.04 to 19.96) in BRCAwt patients (p < .001), highlighting the need for alternative strategies specifically in this genetically defined subgroup.

• Patients with prior PARP inhibitor exposure: As PARP inhibitor maintenance has become standard in earlier lines, a growing proportion of PROC patients have prior PARPi exposure at the time of platinum-resistant relapse. In the PICCOLO trial of MIRV in recurrent platinum-sensitive ovarian cancer, the objective response rate among participants with progressive disease while on or within 30 days of prior PARPi (n=59) was 45.8% (95% CI 32.7% to 59.2%), confirming that FRα-directed therapy retains activity in this post-PARPi population.

• Patients with ADC resistance: Resistance to ADCs, including through payload resistance and target antigen downregulation, represents an emerging unmet need as MIRV use expands. Future strategies under investigation include pairing ADCs with replication stress inhibitors such as ATR inhibitors and WEE1 inhibitors, and integrating next-generation immuno-oncology platforms such as bispecifics, T-cell engagers, and cancer vaccines to overcome resistance mechanisms.

DENALI Study Design and Azenosertib's Path Forward in Ovarian Cancer

Several pivotal trials have evaluated novel agents and combinations in platinum-resistant ovarian cancer (PROC), spanning chemotherapy, targeted therapy, immunotherapy combinations, and antibody-drug conjugates. The trials vary considerably in design, patient population, and primary endpoints, reflecting the heterogeneous therapeutic landscape in this setting.

The knowledge base does not have sufficient information on this aspect.

Cyclin E1: Guiding a New Era for Ovarian Cancer Treatment

The interim overall survival data for azenosertib in platinum-resistant ovarian cancer represents a pivotal moment for patients facing this aggressive disease. The stark difference in outcomes between Cyclin E1-positive and Cyclin E1-negative patients—a median OS of 15.8 months versus 7.5 months—underscores the profound impact of precision medicine in oncology. This finding not only validates azenosertib, a WEE1 inhibitor, as a promising therapeutic option but also firmly establishes Cyclin E1 as a critical predictive biomarker.

For clinical teams, this means a potential new avenue for patient selection, allowing for targeted treatment that maximizes efficacy in those most likely to respond. Research indicates that Cyclin E1 overexpression is a common oncogenic driver in gynecological malignancies, leading to heightened replication stress and genomic instability, which WEE1 inhibitors are designed to exploit. This targeted approach could significantly improve outcomes in a population that has exhausted many standard therapies.

However, the path forward is not without considerations. While the press release noted no new safety signals, prior studies with WEE1 inhibitors have highlighted hematological toxicities, such as neutropenia and thrombocytopenia, which could still be a concern for patient management and dose optimization. Furthermore, the dynamic nature of cancer means that adaptive resistance can emerge, with mechanisms like ROR1-PI3K/AKT signaling potentially limiting the long-term durability of monotherapy responses. The practical implementation of Cyclin E1 testing in routine clinical practice will also be crucial, requiring robust and accessible diagnostic tools. Looking ahead, the synergy of WEE1 inhibitors with DNA damaging agents suggests potential for combination therapies, and the use of circulating tumor DNA (ctDNA) as an early molecular response biomarker could further refine treatment monitoring and patient management, offering a rapid and reliable surrogate for efficacy. This evolving landscape points to a future where targeted therapies, guided by precise biomarkers, reshape the treatment paradigm for ovarian cancer.